ALXO Historical PE Ratio Notes

— ALX Oncology Holdings (ticker: ALXO) is a clinical-stage immuno-oncology company focused on developing therapies that help the body's immune system recognize & attack cancer. Their lead product candidate, evorpacept (ALX148), is designed to block the CD47 pathway—a so-called ȁcdon't eat meȁd signal that cancer cells use to evade immune detection. Since ALXO is not yet profitable and is primarily in the R&D phase, the company's historical P/E ratio is either extremely high or not meaningful (often shown as ȁcN/Aȁd or negative), since the ȁcEȁd (earnings) part of the ratio is negative or minimal. For investors analyzing historical price, earnings, & P/E data, it's important to understand that typical valuation metrics like P/E ratio may not provide useful insights for a clinical-stage biotech. Instead, ALXO's valuation at different points in time reflects market sentiment about the prospects for its drug trials, partnership announcements, & progress toward commercialization, rather than stable or growing earnings. Therefore, fluctuations or apparent anomalies in ALXO's historical P/E ratio are tied to the company's high-risk/high-reward clinical stage, rather than its current or past profitability.

On this page we presented the ALXO Historical PE Ratio information for ALX Oncology Holdings' stock. The average ALXO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ALXO historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ALXO historical PE result, against the recent PE: when this page was posted on 8/6/2026, the most recent closing price for ALXO had been 2.11, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on ALXO or any other given stock, valuation analysis for ALXO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate ALX Oncology Holdings PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ALXO. Thanks for visiting, and the next time you need to research ALXO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.